The Influence of Finasteride on the Development of Prostate Cancer
| العنوان: | The Influence of Finasteride on the Development of Prostate Cancer |
|---|---|
| المؤلفون: | Michael M. Lieber, Anne Ryan, Scott M. Lippman, R. Duane Cespedes, Gary J. Miller, Susie M. Carlin, Leslie G. Ford, Phyllis J. Goodman, M. Scott Lucia, Charles A. Coltman, Connie M. Szczepanek, Catherine M. Tangen, JN Atkins, John Crowley, Ian M. Thompson |
| المصدر: | New England Journal of Medicine. 349:215-224 |
| بيانات النشر: | Massachusetts Medical Society, 2003. |
| سنة النشر: | 2003 |
| مصطلحات موضوعية: | Gynecology, medicine.medical_specialty, Prostate biopsy, medicine.diagnostic_test, business.industry, medicine.drug_class, Urology, General Medicine, medicine.disease, Antiandrogen, Dutasteride, chemistry.chemical_compound, Prostate cancer, medicine.anatomical_structure, chemistry, Prostate, Finasteride, Medicine, Prostate Cancer Prevention Trial, business, Testosterone |
| الوصف: | background Androgens are involved in the development of prostate cancer. Finasteride, an inhibitor of 5 a -reductase, inhibits the conversion of testosterone to dihydrotestosterone, the primary androgen in the prostate, and may reduce the risk of prostate cancer. methods In the Prostate Cancer Prevention Trial, we randomly assigned 18,882 men 55 years of age or older with a normal digital rectal examination and a prostate-specific antigen (PSA) level of 3.0 ng per milliliter or lower to treatment with finasteride (5 mg per day) or placebo for seven years. Prostate biopsy was recommended if the annual PSA level, adjusted for the effect of finasteride, exceeded 4.0 ng per milliliter or if the digital rectal examination was abnormal. It was anticipated that 60 percent of participants would have prostate cancer diagnosed during the study or would undergo biopsy at the end of the study. The primary end point was the prevalence of prostate cancer during the seven years of the study. results Prostate cancer was detected in 803 of the 4368 men in the finasteride group who had data for the final analysis (18.4 percent) and 1147 of the 4692 men in the placebo group who had such data (24.4 percent), for a 24.8 percent reduction in prevalence over the seven-year period (95 percent confidence interval, 18.6 to 30.6 percent; P |
| تدمد: | 1533-4406 0028-4793 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_________::ed84d69cafcd1fe93311f335c50cb017 https://doi.org/10.1056/nejmoa030660 |
| رقم الأكسشن: | edsair.doi...........ed84d69cafcd1fe93311f335c50cb017 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15334406 00284793 |
|---|